Progress and Hurdles for Follow-on Biologics

被引：38
|
作者：
Sarpatwari, Ameet [1 ]
Avorn, Jerry
Kesselheim, Aaron S.
机构：
[1] Brigham & Womens Hosp, Dept Med, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2015年 / 372卷 / 25期
关键词：
D O I：
10.1056/NEJMp1504672
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：2380 / 2382
页数：3
相关论文
共 50 条
  • [21] Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics
    Wright, Eugene E., Jr.
    Blevins, Thomas C.
    Reed, Beverly
    Pollom, Roy Daniel
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (04): : S22 - S27
  • [22] Current Regulatory and Legal Considerations for Follow-On Biologics
    Kingham, R. F.
    Lietzan, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (05) : 633 - 635
  • [23] Active Surveillance of Follow-on Biologics: A Prescription for Uptake
    Sarpatwari, Ameet
    Gagne, Joshua J.
    Levidow, Nicole L.
    Kesselheim, Aaron S.
    DRUG SAFETY, 2017, 40 (02) : 105 - 108
  • [24] The challenge of follow-on biologics for treatment of multiple sclerosis
    Reingold, S. C.
    Steiner, J. P.
    Polman, C. H.
    Cohen, J. A.
    Freedman, M. S.
    Kappos, L.
    Thompson, A. J.
    Wolinsky, J. S.
    NEUROLOGY, 2009, 73 (07) : 552 - 559
  • [25] THE CHALLENGE OF FOLLOW-ON BIOLOGICS FOR TREATMENT OF MULTIPLE SCLEROSIS
    Rivera, Victor M.
    NEUROLOGY, 2010, 74 (10) : 864 - 864
  • [26] Manufacturing issues shape follow-on biologics debate
    Wechsler, Jill
    Pharmaceutical Technology, 2007, 31 (06) : 30 - 40
  • [27] Active Surveillance of Follow-on Biologics: A Prescription for Uptake
    Ameet Sarpatwari
    Joshua J. Gagne
    Nicole L. Levidow
    Aaron S. Kesselheim
    Drug Safety, 2017, 40 : 105 - 108
  • [28] Japanese Biotech Patenting Strategies in the Era of Follow-On Biologics
    Tessensohn, John A.
    Yamamoto, Shusaku
    BIOTECHNOLOGY LAW REPORT, 2009, 28 (04) : 483 - 496
  • [29] What follow-on biologics mean for the future of the biotechnology industry
    Hussain, Ajaz S.
    Woollett, Gillian R.
    BIOPHARM INTERNATIONAL, 2007, 20 (11) : 32 - +
  • [30] A Tolerance Interval Approach to Assessing the Biosimilarity of Follow-On Biologics
    Chen, Chi-Tian
    Tsou, Hsiao-Hui
    Hsiao, Chin-Fu
    Lai, Yi-Hsuan
    Chang, Wan-Jung
    Liu, Jung-Tzu
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2017, 9 (03): : 286 - 292
12345